Interplay between SAFE and RISK pathways in sphingosine-1-phosphate-induced cardioprotection
ContributorsSomers, Sarin J; Frias, Miguel; Lacerda, Lydia; Opie, Lionel H; Lecour, Sandrine
Published inCardiovascular drugs and therapy, vol. 26, no. 3, p. 227-237
Publication date2012
Abstract
Keywords
- Animals
- Cardiotonic Agents/pharmacology/therapeutic use
- Extracellular Signal-Regulated MAP Kinases/metabolism
- Forkhead Transcription Factors/metabolism
- Lysophospholipids/pharmacology/therapeutic use
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Myocardial Infarction/drug therapy/metabolism/pathology
- Myocardial Reperfusion Injury/drug therapy/metabolism/pathology
- Proto-Oncogene Proteins c-akt/metabolism
- STAT3 Transcription Factor/genetics/metabolism
- Signal Transduction/drug effects
- Sphingosine/analogs & derivatives/pharmacology/therapeutic use
- Tumor Necrosis Factor-alpha/genetics/metabolism
Affiliation
Research group
Citation (ISO format)
SOMERS, Sarin J et al. Interplay between SAFE and RISK pathways in sphingosine-1-phosphate-induced cardioprotection. In: Cardiovascular drugs and therapy, 2012, vol. 26, n° 3, p. 227–237. doi: 10.1007/s10557-012-6376-2
Main files (1)
Article (Published version)
Identifiers
- PID : unige:31964
- DOI : 10.1007/s10557-012-6376-2
- PMID : 22392184
ISSN of the journal0920-3206
